Business
Race Oncology (ASX:RAC) share price slides on a new melanoma preclinical study
The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98.
Race Oncology share price unfazed by Bisantrene study
Race Oncology focuses on the development of cancer-targeting drugs in an effort towards better outcomes. The company’s flagship drug is Bisantrene, a small molecule inhibitor of the fat mass and obesity-associated (FTO) protein. A link between FTO and a range of cancers has led Race to investigate Bisantrene further.
According to the release, Race has now entered…
-
Noosa News21 hours agoPilot left with life-threatening burns to his body as plane crashes to ground in Raglan, Queensland
-
Noosa News15 hours agoTeenage girl killed in house fire in Lawnton, Queensland as police probe potential e-bike link
-
Noosa News22 hours agoWhen will my HECS debt be cut? Millions of Australians wake to 20 per cent cut
-
General24 hours agoTitanic passenger’s watch sets record at UK auction